Here are five observations:
1. The FDA approved Viberzi at 75 mg and 100 mg for a 12-week treatment.
2. Patients suffering from IBS-D can take the pill twice a day.
3. Allergen’s stock rose 0.49 percent during the last trading session, reaching $293.22.
4. The company outperformed the S&P 500 by 9.6 percent.
5. Allergen develops medical aesthetics, generic, branded generic, biosimilar and over-the-counter pharmaceutical products.
More articles on gastroenterology:
GI physician leader to know: Dr. David Greenwald of Mount Sinai Hospital
Olympus’ modified duodenoscope receives FDA approval, EndoChoice stock lowered to “sell” & more — 4 GI/endoscopy company key notes
Are gastroenterologist’s patient biases & political leanings related? 4 statistics
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
